In multivariate Cox proportional hazards regression analyses, CDCA2 displayed prognostic impact independently of IPI and ABC/GCB in R-CHOP treated patients, whereas no prognostic significance was observed in RB-CHOP treated patients (Figure 2C,D, Supplementary Table S3A,B), suggesting CDCA2 as a marker of a bortezomib response. This evidence concerns the gene CDCA2 and aneurysmal bone cyst.